Shaperon샤페론

Shaperon remains a loss-making drug developer with tiny revenue, a shares price down about 82% over a year, and a trading-halt and listing-rule warning history.

Shaperon is a Korean biotech developing drug candidates, including an atopic dermatitis treatment in US trials and an Alzheimer's treatment in Korean trials. Its filed results show trailing revenue of about ₩323M against an operating loss of about ₩15.6B over the half-year to June 2026, with negative free cash flow of about ₩14.5B. The share price closed at ₩2,320 on 19 October 2026, with a market value of about ₩21.5B.

What stands out

• Trailing revenue is only about ₩323M, while the operating loss is about ₩15.6B, so the operating margin is deeply negative at roughly -4,841%.
• Cash is about ₩991M against a trailing free cash outflow of about ₩14.5B, which the data does not show how the company plans to fund.
• The price is down 81.9% over one year and 9% over one month; the 52-week low in the data is ₩0, which looks like a data gap rather than a real price.
• Recent filings include a preliminary earnings release, a major management matter, two trading halts, and a notice about a share-price-below-₩1,000 designation concern.
• Recent news coverage (Chosun Biz, mid-October 2026) covers a planned co-development of Nuselin and a presentation at BioJapan 2026; the data does not show any financial terms.

What to watch

• The full results and any management matter disclosed in the September and October filings, including the preliminary earnings release from 1 October.
• Any further trading halts, the outcome of the designation concern under management, and any fundraising or convertible bond actions.
• Progress of the atopic dermatitis and Alzheimer's trials and whether the Nuselin co-development or technology transfer produces disclosed terms; the data gives no analyst forecasts or fair value estimate.